The VP.S ENCORE™ Device is designed to have a significant impact on patients awaiting lifesaving or life-altering transplant surgeries by extending the viability of organs outside the body, and by extending the time for transport compared to traditional ice cooler technology. The primary goals in developing VP.S ENCORE™ device include the ability to expand the donor organ pool, optimizing matching of the donor organs, and to minimize rejection.
The initial target organ for use of the VP.S ENCORE™ device is the heart. Outcome data collected to demonstrate optimal performance of the VP.S ENCORE™ device in animal studies include:
- Minimal or no edema after preservation
- Evidence demonstrating switching from anaerobic metabolism to aerobic metabolism during preservation
- Tissue biopsies that indicate significantly lower inflammatory and cellular death markers when compared to the standard of care
- Significantly higher contractility than hearts preserved with the standard of care, as tested in vitro using a working heart model on a Langendorff Device.
Preclinical testing demonstrated excellent preservation using organ grafts in the animal models and human hearts donated for research.
In addition to having a positive impact on the lives of patients awaiting transplants, the VP.S ENCORE™ device is designed to allow surgeons and surgical centers to better schedule and manage their procedures. Moreover, should more organs become available for transplant, surgeons will ideally be able to perform more lifesaving and life-transforming surgeries.
If you are interested in receiving periodic updates, please call us at (210) 884-8071 or email us at email@example.com.